Lilly to stop development of lymphoma drug enzastaurin

05/12/2013 | Genetic Engineering & Biotechnology News

Eli Lilly & Co. said it would stop developing the experimental drug enzastaurin as a treatment for diffuse large B-cell lymphoma after obtaining unfavorable results from a late-stage trial. The drug failed to significantly improve disease-free survival against placebo in patients at high risk of relapse after chemotherapy.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC